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We examined hepatocellular carcinoma mortality in relation to coffee consumption and anti-hepatitis C virus (HCV) antibody
seropositivity in a nested case–control study involving 96 cases. The multivariate-adjusted odds ratios (95% confidence interval) for
daily coffee drinkers vs non-drinkers were 0.49 (0.25–0.96), 0.31 (0.11–0.85), and 0.75 (0.29–1.92) in all cases, in HCV-positive and
in HCV-negative individuals, respectively.
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The inverse associations between coffee consumption and the
risk of hepatocellular carcinoma (HCC) have recently been
reported not only from case–control studies (Gallus et al,
2002; Gelatti et al, 2005; Ohfuji et al, 2006; Montella et al, 2007;
Tanaka et al, 2007) but also from Japanese cohort studies (Inoue
et al, 2005; Kurozawa et al, 2005; Shimazu et al, 2005). Cohort
studies are superior to case–control studies in avoiding recall and
selection bias (Ohfuji et al, 2006). Previous prospective studies
(Inoue et al, 2005; Kurozawa et al, 2005; Shimazu et al, 2005),
however, did not consider the infection status of hepatitis C virus
(HCV) at baseline. As HCV is the major cause of HCC in Japan and
certain other countries (Heathcote, 2004), it would be important if
protective factors against HCC could be found among the HCV-
positive population. We therefore examined the relation of coffee
use to risk of death from HCC by HCV infection status in a case–
control study nested in a large cohort study in Japan.
MATERIALS AND METHODS
We carried out a nested case–control study as a part of the Japan
Collaborative Cohort Study for Evaluation of Cancer Risk
Sponsored by the Ministry of Education, Culture, Sports, Science
and Technology of Japan (Mobusho), details of which are
described elsewhere (Tamakoshi et al, 2005). It involved 110792
individuals, aged 40–79 years at baseline, from 45 areas
throughout Japan. A self-administered questionnaire on lifestyle
and medical factors was distributed in 1988–1990 covering
habitual coffee consumption, with possible responses including
‘scarcely any’, ‘1–2 cups per month’, ‘1–2 cups per week’, ‘3–4
cups per week’, and ‘almost every day’. Those who answered
‘almost every day’ were asked to report the number of cups
consumed per day. The questionnaire was validated using four
3-day dietary records as a reference; the Spearman correlation
coefficient was 0.79 (Iso et al, 2006).
In addition, those participants who underwent health-screening
checks sponsored by municipalities were asked to donate blood
samples at baseline and eventually, 39242 subjects in 37 study
areas did so (Tamakoshi et al, 2005), these being stored at  801C
until analysed. Informed consent was obtained individually from
subjects, except in certain areas in which it was provided at the
group level after details had been explained to community leaders.
The Ethics Committee of Kurume University School of Medicine
approved this study.
We used population registries in the municipalities to determine
the vital and residential status of the subjects. Causes of death were
confirmed by review of death certificates with permission from the
Ministry of Internal Affairs and Communications. Cases eligible
for the present study consisted of those who died of HCC, ICD-10
coded C22.0.
During follow-up through the end of 1999, 106 eligible cases
were identified among the participants with serum samples, from
which two were excluded with insufficient samples and eight
without information on coffee consumption. Of the remaining 96
cases, 60 (62.5%) were positive for HCV Ab. As potential controls,
sera of 11513 subjects from the same geographical areas as the
cases were also screened for HCV Ab. After excluding those with
missing data on coffee drinking, we found 912 HCV-Ab-positive
subjects (8.2%) and 10175 HCV-Ab-negative ones. From these, we
chose as many controls per case as possible, matching for age
(same 5-year strata), sex, and HCV-Ab seropositivity, selecting 420
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HCV-Ab-negative ones (84 controls per case).
Statistical analysis
Study participants were categorised into three groups by coffee
consumption, that is, X1cupday
 1, o1cupday
 1 (‘1–2cups
month
 1’, ‘1–2cupsweek
 1’, or ‘3–4cupsweek
 1’), and non-
drinkers. Daily drinkers could not be further subdivided because
of their small numbers. Odds ratios (OR) and the 95% confidence
intervals (CI) by HCV-Ab positivity were estimated considering
the matching using conditional logistic models (Breslow and Day,
1980). Multivariate-adjusted OR were also computed after adjust-
ment for area, smoking and drinking habits, and history of
diabetes mellitus and liver diseases. For alcohol drinking, subjects
were categorised into never drinkers, former drinkers, or current
drinkers who consumed o2o rX2 Japanese drinks per day (one
Japanese drink is equivalent to 23g of ethanol) in this analysis. The
linear trend in HCC risk was tested by treating the coffee
consumption category as an ordinal variable. The heterogeneity
in the association of coffee drinking by HCV status was statistically
tested by incorporating a multiplicative interaction term between
HCV status and the coffee consumption category in the model.
Missing values for each covariate were treated as an additional
category in the variable and were included in the model. All
P-values were two-sided, and all the analyses were carried out
using the Statistical Analysis System version 9.1 (SAS Institute,
Cary, NC, USA).
RESULTS
Cases and controls were well matched on age and sex in both the
HCV-positive and -negative groups. The mean ages7s.d. were
62.976.6, 62.476.2, 63.677.5, and 63.477.3 years in the HCV-
positive cases and controls and the HCV-negative cases and
controls, respectively. Women accounted for 35.0% of both the
HCV-positive cases and controls, and 36.1% of the HCV-negative
cases and controls. Case subjects were more likely to currently
smoke than controls in the HCV-positive group (56.6 vs 35.8%).
Former drinkers and a history of diabetes mellitus and liver
diseases were much more common in cases than in controls. In the
HCV-positive cases, the proportions of former drinkers and those
with diabetes and liver diseases were 28.6, 15.0, and 56.7%,
respectively, against 6.6, 5.0, and 20.7% in the controls. The
corresponding figures were 14.3, 13.9, and 27.8% in the HCV-
negative cases and 4.4, 4.5, and 4.4% in the controls.
Drinking one or more cups of coffee per day was inversely
associated with HCC mortality among all subjects (Table 1:
multivariate-adjusted OR (OR2), 0.49; 95% CI, 0.25–0.96) and the
anti-HCV-positive group (OR2, 0.31; 95% CI, 0.11–0.85). Although
daily coffee drinkers in the HCV-negative group showed OR below
unity, they did not reach statistical significance. The heterogeneity
in the association of coffee drinking by HCV status was also not
significant in the multivariate model (P ¼ 0.61).
DISCUSSION
Coffee drinking was significantly associated with a decreased risk of
death from HCC in all subjects and those infected with HCV. Our
results from this prospective cohort study support the findings in
some (Gelatti et al,2 0 0 5 ;O h f u j iet al, 2006), although not all
(Montella et al, 2007), case–control studies that suggested a
protective effect of coffee among HCV-positive individuals. Some
patients with hepatitis or liver cirrhosis, however, may have decreased
coffee consumption at their physician’s advice or due to impaired
caffeine metabolism in the liver (Hasegawa et al, 1989). Observational
studies among subjects without active hepatitis or intervention
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ystudies will further clarify the role of coffee in the possible prevention
of HCV-related HCC. Further, because a nonsignificant inverse
association was found between coffee consumption and HCC risk in
HCV-negative individuals in the present study, investigations with
more HCV-negative HCC cases are also warranted.
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